| Literature DB >> 28009354 |
Steffi Gieseler-Halbach1, Stefan Meltendorf1, Mandy Pierau1, Soenke Weinert2, Florian H Heidel3,4, Thomas Fischer3, Juliane Handschuh5, Ruediger C Braun-Dullaeus2, Martin Schrappe6, Jonathan A Lindquist7, Peter R Mertens7, Ulrich Thomas5, Monika C Brunner-Weinzierl1.
Abstract
Deregulated proliferation is key to tumor progression. Although unrestricted proliferation of solid tumor cells correlates with the cold-shock protein Y-box (YB)-binding protein-1 accumulation in the nuclei, little is known about its expression and function in hematopoietic malignancies, such as T-cell acute lymphoblastic leukemia (T-ALL). Here we show that YB-1 protein is highly enriched in the nuclei of activated T cells and malignant human T-ALL cell lines but not in resting T cells. YB-1 S102 mutations that either mimic (S102D) or prevent phosphorylation (S102N) led to accumulation of YB-1 in the nucleus of T cells or strictly excluded it, respectively. Inactivation of ribosomal S6 kinase (RSK) was sufficient to abrogate T-cell and T-ALL cell proliferation, suggesting that RSK mediates cell-cycle progression, possibly dependent on YB-1-phosphorylation. Indeed, phosphomimetic YB-1S102D enhanced proliferation implying that S102 phosphorylation is a prerequisite for malignant T-cell proliferation. At initial diagnosis of T-ALL, YB-1 localization was significantly altered in the nuclei of tumor blasts derived from bone marrow or peripheral blood. Our data show deregulated YB-1 in the nucleus as a yet unreported characteristic of T-ALL blasts and may refine strategies to restrict progression of hematopoietic tumors.Entities:
Mesh:
Substances:
Year: 2016 PMID: 28009354 PMCID: PMC5299718 DOI: 10.1038/cdd.2016.141
Source DB: PubMed Journal: Cell Death Differ ISSN: 1350-9047 Impact factor: 15.828